United States Patent 8,217,057 (Crystalline (R)-Free Base): What Is Claimed, What Is Actually Covered, and How the Patent Estate Likely Blocks Generic Entry
US Drug Patent 8,217,057 is a crystal-form patent anchored to a specific PXRD fingerprint for the free base of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine (the “crystalline free base”). It claims (i) the crystalline free base with a substantially identical PXRD pattern to FIG. 1, (ii) dependent embodiments defined by specific peak sets and 2θ tolerances, and (iii) downstream dosage forms (pharmaceutical composition and capsules) with large dose-weight ranges.
What is the scope of US Patent 8,217,057 claims (crystalline free base PXRD fingerprint)?
Independent claim 1: how broadly “crystalline form” is actually defined
Claim 1 covers:
- “A crystalline form of free base of” the specified (R)-amine.
- The crystalline form must have a powder X-ray diffraction pattern substantially the same as shown in FIG. 1.
Practical scope: The claim is broad on identity of the “form,” but constrained by material characterization. “Substantially the same” is the key legal lever: it typically invites disputes about whether an accused sample’s PXRD patterns match closely enough (peak positions, relative intensities, and the presence/absence of diagnostic peaks).
Key claim anchor: PXRD vs. other solid-state features
The claim uses PXRD pattern matching rather than:
- a melting point range,
- a spectroscopic fingerprint (IR/Raman),
- a specific crystallographic space group,
- polymorph naming,
- particle size/shape,
- or solid-state stability metrics.
That means enforcement and validity arguments usually turn on:
- whether a competitor’s crystal form is another polymorph/solvate but still “substantially the same” by PXRD,
- whether the competitor can produce a version with shifted peaks outside the tolerated windows (see dependent claims).
What specific PXRD peak targets are protected in dependent claims 2–5?
Dependent claims define numerical peak selection. This narrows “substantially the same” into testable diffraction windows.
Claim 2: single diagnostic peak
Claim 3: two peaks
- Peaks at 2θ = 17.3 ± 0.1 and 19.7 ± 0.1
Claim 4: three peaks
- Peaks at 2θ = 15.7 ± 0.1, 17.3 ± 0.1, and 19.7 ± 0.1
Claim 5: four peaks
- Peaks at 2θ = 15.7 ± 0.1, 17.3 ± 0.1, 19.7 ± 0.1, and 26.8 ± 0.1
How this narrows design-around space
For an accused infringer, the easiest commercial path to avoid infringement is typically to make a crystal form whose PXRD peaks:
- shift beyond ±0.1 degrees on at least one of the required diagnostic angles, or
- removes one required diagnostic peak (e.g., eliminating the 26.8 ± 0.1 peak if proceeding under claim 5).
Because each dependent claim changes the set of required peaks, infringement can be argued under any subset theory. A competitor trying to “break” claim 5 by moving the 26.8 peak might still land on claim 4 or claim 3 if other required peaks align.
Net effect: The tightest numerical constraints are those in claims 3–5. They create a relatively clear analytical infringement gate keyed to PXRD.
What formulations and dosage forms are covered beyond the crystalline free base?
Claim 6: pharmaceutical composition
- Covers “a pharmaceutical composition comprising the crystalline form of claim 1.”
Scope: Compositions can contain excipients, carriers, and formulation components, as long as the crystalline form is present.
Claims 7–10: capsule dosage form and dose range
- Claim 7: “a capsule comprising the pharmaceutical composition”
- Claim 8: capsule comprising 0.1 to 200 mg
- Claim 9: capsule comprising 25 to 150 mg
- Claim 10: capsule comprising 50 to 100 mg
Practical scope:
- Capsules are expressly covered; tablets, film-coated oral solids, powders in sachets, and injectables are not expressly claimed here (unless they fall under composition claim 6 by construction and infringement theory).
- The dose ranges are broad. If the drug is marketed in capsule strengths that fall within 50–100 mg or 25–150 mg, those products sit inside the claim coverage.
- Because these are composition-of-crystalline-form claims, the key issue becomes whether the marketed API is the claimed crystalline free base rather than a different polymorph/solvate or an amorphous form.
What does the claim structure imply about “polymorph” and “solvate” risk?
Even without the specification, the claim strategy indicates:
- The patentee is targeting a specific solid-state form by PXRD.
- The dependent numerical peaks suggest the crystalline form has consistent “signature” peaks.
Infringement risk pattern for competitors:
- If a generic developer selects an alternative crystalline form that is clearly distinct by PXRD, risk drops.
- If the alternative form still produces peaks at 15.7, 17.3, 19.7 and possibly 26.8 within ±0.1, the competitor likely remains exposed to at least claims 1–4 and potentially claim 5.
This is a classic PXRD-driven polymorph enforcement posture: analytical equivalency is the battleground.
How does US 8,217,057 likely fit in a US Orange Book patent estate?
This patent is a listed drug substance/formulation patent type in many estates where:
- the core API is described,
- plus specific crystalline forms,
- plus dosage forms (capsules).
Because the claims include:
- the crystalline form (API solid form),
- a pharmaceutical composition,
- and a capsule with explicit mg ranges,
it is consistent with an Orange Book listing strategy where generic applicants must address whether they can design around the crystalline form or challenge validity/ noninfringement.
Litigation and regulatory behavior typically associated with this kind of claim:
- If a generic ANDA filer chooses a crystalline form different from FIG. 1, they argue noninfringement based on PXRD.
- If they can’t or choose not to, they may pursue Paragraph IV challenges to invalidate the crystalline form claims (anticipation/obviousness, or lack of enablement/definiteness depending on claim construction posture).
Which generic entry routes could avoid infringement for US 8,217,057?
1) Switch the solid state form
The most direct design-around is to use a free base crystalline polymorph/variant whose PXRD does not match “substantially the same” and/or whose peaks are outside the dependent windows.
- Avoid alignment at 19.7 ± 0.1 if possible.
- If avoiding only one peak, note the set progression in claims 2–5. A form that misses only the 26.8 peak could still satisfy claim 4 (and earlier).
2) Use a non-crystalline form
A fully amorphous form is a common alternative in solid-state strategy, but claim 1 requires a “crystalline form.” If the accused product is truly amorphous (and PXRD shows no corresponding crystalline peaks), noninfringement is stronger.
3) Change dosage form
Capsules are claimed. Switching to a different dosage form could reduce exposure for the capsule claims, but claim 6 (composition) still remains if the crystalline form is used.
How strong is the patent’s enforceability based on claim definiteness?
Claim 1 is anchored to PXRD “substantially the same as FIG. 1.” That introduces construction issues:
- “Substantially the same” is a comparative standard, not a fixed numerical list.
- Claims 2–5 provide fixed numerical windows, which typically helps plaintiffs argue objective match on at least those embodiments.
From an enforcement perspective:
- Stronger proof usually comes when an asserted sample matches the specific peak sets in claims 2–5.
- The wider claim 1 still gives plaintiffs flexibility if the accused pattern is close but not identical.
How do these claims create litigation and settlement leverage in ANDA practice?
In ANDA litigation, parties typically focus on:
- what PXRD method and instrument settings were used (can affect peak location and intensity),
- whether the accused API is the same crystalline form (or a close polymorph),
- and whether any differences are outside the dependent windows.
Because dependent claims are numerical, they are well-suited to:
- targeted noninfringement analysis,
- expert testimony comparing diffraction angles,
- and summary judgment strategies where peak positions are uncontested.
Settlement leverage is usually highest where:
- the generic applicant cannot credibly switch solid form without losing bioequivalence/performance,
- and PXRD match looks likely within the windows.
Claim-by-claim scope map (what is covered, what is likely excluded)
| Claim |
Covered subject matter |
Scope driver |
Likely excluded if… |
| 1 |
Crystalline form of the (R)-free base with PXRD substantially like FIG. 1 |
PXRD similarity standard |
PXRD peaks differ materially from FIG. 1 |
| 2 |
Claim 1 form with peak at 19.7 ± 0.1 |
Numerical 2θ |
19.7 peak shifted beyond ±0.1 |
| 3 |
Claim 1 form with peaks at 17.3 ± 0.1 and 19.7 ± 0.1 |
Numerical 2θ set |
One of the two peaks missing or shifted |
| 4 |
Claim 1 form with peaks at 15.7 ± 0.1, 17.3 ± 0.1, 19.7 ± 0.1 |
Numerical 2θ set |
Any required peak outside window |
| 5 |
Claim 1 form with peaks at 15.7 ± 0.1, 17.3 ± 0.1, 19.7 ± 0.1, 26.8 ± 0.1 |
Numerical 2θ set |
26.8 peak absent or outside ±0.1 |
| 6 |
Pharmaceutical composition comprising the crystalline form |
Inclusion of the claimed crystalline API |
Product lacks the crystalline form |
| 7 |
Capsule comprising the composition |
Capsule dosage form |
Non-capsule formats |
| 8 |
Capsule dose 0.1–200 mg |
mg range |
Capsule strength outside range |
| 9 |
Capsule dose 25–150 mg |
mg range |
Outside mg range |
| 10 |
Capsule dose 50–100 mg |
mg range |
Outside mg range |
What is the business impact for investors, BD/licensing teams, and generic competitors?
For generic entrants
The claim set signals that they must plan solid-state development around PXRD peak engineering with tight measurement criteria.
- If the development target crystalline form includes the same diagnostic peaks, noninfringement becomes difficult.
- If they plan an alternative form, it must still perform in terms of dissolution, stability, and bioequivalence.
For brand holders and licensors
This is a defensible posture for crystal form exclusivity because:
- claim 1 uses PXRD pattern matching,
- claims 2–5 define tight numerical peaks,
- and claims 6–10 capture common oral capsule commercialization routes.
In licensing negotiations, this patent can be used to demand:
- confirmation of crystalline form differences,
- or a field-limited grant excluding capsule strengths that map to claims 8–10.
For litigation teams
Most litigation will likely hinge on analytical facts:
- PXRD patterns and peak positions under agreed protocols,
- whether the accused form corresponds to “substantially the same” FIG. 1.
Key Takeaways
- US 8,217,057 is a PXRD-defined crystalline form patent for the (R)-free base of a specific 2-aminopyridine-pyrazole ether scaffold.
- Claim 1 covers any crystal form whose PXRD pattern is substantially the same as FIG. 1.
- Claims 2–5 provide tight numerical PXRD peak windows at 15.7, 17.3, 19.7, and 26.8 (2θ ± 0.1), creating objective infringement gates.
- The estate extends downstream to pharmaceutical compositions (claim 6) and capsules (claims 7–10) with broad mg ranges, meaning the commercial risk is tied to the marketed capsule strength and the API solid-state identity.
- Competitors’ primary design-around is switching to a distinctly different solid-state form (or amorphous form) that breaks at least one key diagnostic peak window.
FAQs
1) Does US 8,217,057 cover the free base in any solid form?
No. It is limited to a crystalline form with PXRD substantially matching FIG. 1, and dependent claims narrow further to specific peak sets and tolerances.
2) If a generic uses a different polymorph, can it still infringe?
Yes, if the alternative polymorph’s PXRD is still “substantially the same” and can satisfy the numerical peak requirements in claims 2–5.
3) Are capsule claims stronger than composition claims in enforcement?
Capsule claims (7–10) are stronger where the accused product is a capsule and strength falls within the mg ranges, but composition claim 6 can still capture non-capsule dosage forms if they include the claimed crystalline form.
4) Which PXRD peaks matter most for design-around?
The dependent claim peaks at 19.7 ± 0.1 (claim 2), 17.3 ± 0.1 and 19.7 ± 0.1 (claim 3), 15.7 ± 0.1, 17.3 ± 0.1, 19.7 ± 0.1 (claim 4), and plus 26.8 ± 0.1 (claim 5).
5) What dosing strengths are covered for capsules?
All capsule strengths that fall within 0.1–200 mg (claim 8), with narrower coverage explicitly identified for 25–150 mg (claim 9) and 50–100 mg (claim 10).
References
- United States Patent 8,217,057 (claims provided in prompt).
